On April 2, 2026 Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies, reported that it will present data supporting its potentially best-in-class KIF18A inhibitor, ATX-295, in a poster presentation at the 2026 AACR (Free AACR Whitepaper) Annual Meeting taking place April 17-22 in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation will feature robust in vitro and in vivo data demonstrating ATX-295’s anti-tumor activity in models of high-grade serous ovarian cancer (HGSOC), squamous non-small cell lung cancer (sqNSCLC), and triple-negative breast cancer (TNBC). Accent’s lead program, ATX-295, is designed to target cancer vulnerabilities derived from genomic and chromosomal instability. These aggressive tumor types share a high prevalence of such instability, representing a large patient population and strong rationale for KIF18A inhibition.
By selectively targeting this dependency, ATX-295 drives rapid cell death in cancer cells burdened with genomic and chromosomal abnormalities, while leaving healthy cells unaffected. The program is currently being evaluated in a Phase 1/2 open-label study enrolling patients with locally advanced or metastatic solid tumors.
"Patients with aggressive, chromosomally instable tumors like squamous non-small cell lung, high-grade serous ovarian, and triple-negative breast cancer face limited durable treatment options and a high risk of disease progression," said Serena Silver, Ph.D., Chief Scientific Officer at Accent Therapeutics. "We are particularly encouraged by these new preclinical findings, which demonstrate compelling activity in squamous lung models. We believe this dataset further supports the potential of our program to address a significant unmet need and reinforces our commitment to advancing innovative therapies for patients who urgently require better options."
Presentation details are as follows:
Poster Title: Robust anti-tumor activity of the novel KIF18A inhibitor, ATX-295, in preclinical models of chromosomally instable tumors
Abstract Number: 6641
Session Title: Multi-Axis Antineopastic Agents
Session Date and Time: Tuesday, April 21, 2:00 PM – 5:00 PM PT
Location: Poster Section 14
Poster Board Number: 2
Presenter: Laura Ghisolfi, Ph.D.
About ATX-295
Accent’s lead program, ATX-295, is a potential best-in-class inhibitor for KIF18A, a mitotic kinesin motor protein critical for cell division in select tumors with chromosomal instability. KIF18A inhibitor treatment results in rapid cell death for cancers with an abnormal number of chromosomes (aneuploid) in vitro and in vivo, while cells with normal numbers of chromosomes (euploid) are unaffected. ATX-295 may address a large patient population across several cancer indications, including ovarian and squamous non-small cell lung cancer. Accent retains full worldwide rights to the KIF18A program, currently being evaluated in an ongoing Phase 1/2 clinical study (NCT06799065) enrolling patients with locally advanced or metastatic solid tumors, including high-grade serous ovarian cancer and squamous non-small cell lung cancer.
(Press release, Accent Therapeutics, APR 2, 2026, View Source [SID1234664158])